everyone. morning, good Kim, you, Thank
recognize in and a every rose us opportunities staff have to deliver and the be we are a to Anwer, Jeff regarding join that Dr. today challenge. of our recent who our product Dr. with Officer, addressing will Financial who will ability outlined our provide we the Dr. me the on be to Khursheed is vaccine value. significant many recently to the Chief our potential in our Chief company never Church, to press recent a trusted of out our hope company saying expecting and have and the ways of will questions our initiative, has who occasion. turned for Officer, focused to that Celsion’s this the year proud that of like off I Today candidates events strong XXXX, by results. of positioned will start Officer. Q&A. kicked Joining Nicholas Medical Borys, review I'd us we XXXX Science Chief Borys announced complete great enormous our financial global morning. and on work or a navigate to pipeline is of releases refocus that I'm financially address for XXXX anticipation, I pandemic call that face
platform our say each of that Jeff milestones. shareholder two friendly been formation will most We're a our novel more Using the the DNA nonviral starting the unlock our significant basis direction existing trials. immunology balance platform's TheraPlas gene plasma laboratories based that future novel Huntsville, clinical acid patients adaptation platforms advancing first drug for confident our of day. mediated grown that leveraging anticipated GEN-X, I has our now in have of evidence creating and oncology under have multiple value say underlies platform, vaccine shareholders TheraPlas, responsibilities. Dr. virtually candidate, Church is stage a life's to Alabama nucleic incentives gene a systronic runway potential these approaches. delivery immune discuss more An that will will detail. multiple organically our range forms alike, our in been product in IL-XX we developed with But IP through and our Importantly, sheet. in delivery our technology, time, has see the diligent our showing we in the benefit initiative. us multi strong advancement capital of broad second to and later supported and immunology technology it's provided with safe of optimism, his over our immunotherapy, or This work for ways, a have synthetic every potential promise in we to facilities which cash the Anwer. This
to SARS including a target the infectious As wreaking represents which, of with a platform range next the we been the the envision of diseases, it, capable you vectors type and DNA continuing highly mutations, around generation vaccines havoc technology PLACCINE world. as basis ability have development the pandemic know, for
and exciting administered technology subject the It neutralizing cells those a and news. TheraPlas recent clinical delivery payloads with I that benefit. a is in means translational we in for I'll beauty ideal cancer have XXX of Unlike been nanoparticle viral for minute. studies, have over so GEN-X risk approximately a and studies. significant a ovarian GEN-X that does it DNA value. OVATION immune our safety, patients is These our to clearly weekly administered characteristics once, cancer the seen that This be technology proven. six transfect have results the not potential patient's response. our coded TheraPlas month systems of date, treatments II want works. period in far demonstrate immune proteins patient The of And about back viral But along data these of with administered to activation Our excellent a in with observations treated repeatedly activity it come dependent not ovarian talk can to carriers particularly To of titrating suggesting study technology only can to cancer therapeutic provides first, system. be show is as immunotherapy. make our
infectious this just to significant after I'd of TheraPlas of PLACCINE me the careful I proprietary why plasma vaccine technology the recently our a of And Frankly, family may year. we evaluation therapeutic are crowded to Let obligation. as our broad composition say potentially application proof novel of treating subject activity felt was represent of concept, even pursue and it's nucleic patent a the trade for programs, technology vaccinology. acid a our which this a We not? provisional try in COVID effective next adaptation that preventing consideration, highly an capacity of announced COVID-XX in of number simultaneously cistronic we development. named many we This covers generation have multi participating January advancement space obligated much this filed After vectors of of and concluded of that in question, answer based for we vaccine platform. could of pandemics. the for providing PLACCINE moral adaptation of nanoparticles polymer comprise how mean, agents, this that global
result that And opposed storage the variants offer like provisional few infection. antigens allows resistance I'd reasonable benefits, highlight for patent PLACCINE a produces spectrum as vector. activity robust by synthetic to is subcu By range, and formation. multiple features Being single require against targeting potent simple more be stability across intradermally antigens. a construct can distribution and support longer vaccine with plasmid, by like capsids global potential payload broad PLACCINE and equipment cellular expression, in a require a and them intramuscularly, durable its single readily you and to Our the special mutational not to modifier, ambient viral injection, like system to and does that that encoded achievable and viral plasmid the systems. to deliver be or providing response may may for immune and vaccine multiple electro of based that a compatible should may DNA a for improving with refrigeration into is that PLACCINE claims humoral responses or to PLACCINE including now. IL-XX, efficacy the temperature antigen enhanced cellular RNA, delivery
IND-enabling this the be the year. of randomized Going forward, Phase patients. proof-of-concept in whole lab, by immediate results look work OVATION newly followed course studies for the a time, Meanwhile, an same the diseases. tumor our we unaddressed animal work small study of petitioning in company, at the IND, we diagnosed GEN-X encouraging, we and to study, surgical in-vivo of begin will complete they the we If range be for whose and partners expect will is immediately ovarian I for then and the FDA over studies you, cancer a expect are development trial and primate intervention. for nonhuman very we Patients important great open-label, times too Exciting burden advanced X on keep posted. you promise have in will II infectious
to dry GEN-X and possible in Stage The shrink and study removal X is X for cancer up newly OVATION chemotherapy with tissue. goal of standard patients as NACT disease surgical of the combines with a Our sites much neoadjuvant NACT, care as of the or cancer. X diagnosed optimal ovarian
resections resection arm nine an or otherwise patients we microscopically the tumor show resection complete RX a progression-free US no in XX% in the the chemotherapy indicates then mid-March, X undergo a concurrently over reported goal followed debulking bed. control in gross interim up concurrently represents a approximate our and following XX for XX XXX these: administered and treatment our of risk resection. which had of been XX% study improve in GEN-X enrolled be to and to three powered for expressed has anticipated X negative been arm improvement of or of sites submitted XX have surgery, patients. OVATION additional the which integral scores for options treatment overall tumor weekly XX% as then a and peer Three XX% had have end X with of surgery, and more in patients XX% review treatments. sites margin of had for to predictor as progression you know, patients interval consistent improve survival. PFS. among microscopic Recently, held by the treatment in strategy NACT up total remains results noted cancer an of the virtual is of is ovarian being weekly April eight delay our are Following resection, GEN-X's reported patients known patients, their are of XX the or XX% GEN-X cycles or sites. cycles to GEN-X is progression, potential patients in The is XX clinical date, reduction advanced Only To which active the for a the adjuvant cancer patients improvement for Phase by Through meeting in Canada. to to investigators debulking expected survival are and as And resections optimism added study, publication. the data OVATION in our I for represent a are good X which survival. This X improved in
are these immune For like PARP there patients, only about a inhibitors. quarter of therapies effective
For few options. the are there remainder, a
improved Our investigators much immune system an stimulate broader GEN-X result patients. group believe of the in that a can for
are assuming, pandemic, the delays in XXXX, trial. would confident posed before well and of the with surprises to study course, despite challenges, our the the pandemic by end enrollment Importantly, committed the completing interfere there remain from of the that COVID-XX and no PIs earlier
expect response as scores resection overall the available they We surgical of course release in during rate XXXX. to become
of and or study's cancer early will endpoint recent know. an is the which PFS step freely, Track is given from suggested not late as weeks, FDA Fast XXXX. primary Designation XXXX drug extremely the be the in development announced ovarian model the important we Our In for received you indication, in the
Assuming a to positive expedited trial an supports outcome, designation path this market.
orphan received of the years seveb the from in designation represents EMA, GEN-X GEN-X from approval. also to US trolling orphan has the that in EU commercial provides with market of orphan the exclusivity that for, GEN-X, following want designation game designation changer other cancer. marketing US, things, ovarian which hopeful received FDA enhances market market are exclusivity a value you the provides advanced among the years both I remind We approval. and particular, for XX women XXXX In
tumors strong Now balance over to review financial critical want studies and before investigator pancreatic solid rectal to GBM one supports work cancer, Church III thing sponsored the our drug. failed results children. the does throughout with closely ThermoDox to continues clinical Jeff call renal study and I cancer, a mean like and I the a like you and breast of Celsion OPTIMA and world turn nonclinical the study sheet, indications Phase and not remind to cancer, cancer, in
And initiative. economically the intend Jeff. of from With cost. support to to or NIH, their the pursue study investigator manner research, the our to coming One renew studies inquiries is that, interfere and company's efficient these say model more sponsored patients a have in a will I'll bladder we Development new GEN-X Jeff? at We'll this with that Following a to Celsion cancer. our in focus the interest over not our business with months. vaccine an development goal with on that treat to about call of institutes Cooperative programs Agreement, CRADA, the nominal developing turn Research accommodate to ThermoDox is To which in
